Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

IPOs at three biotechs last week tempted insiders to make huge share purchases. This spilled over into buying at a couple of ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup ...

Moleculin Biotech shares were up 12% to $2.65 after the company said it saw positive in vivo efficacy data of Annamycin in lung metastatic models of sarcoma. The stock is approaching its 52-week low ...

The biotechnology industry hopes the new Vigyan Dhara initiative of the Union government with a Rs. 10,000 crore outlay will result in better fund utilisation, and improve efficiency with its support ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

Moleculin Biotech said it saw positive in vivo efficacy data of Annamycin in orthotopic and experimental lung metastatic models of sarcoma. The clinical-stage pharmaceutical company saw the results in ...